Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions

Abstract

We demonstrate the feasibility of SBC of apheresis platelets to mitigate bacterial risk. SBC is lower cost than alternative measures (e.g., pathogen reduction and point-of-release testing) and can be integrated into workflow at hospital transfusion services.